The ALK translocation in advanced non-small-cell lung carcinomas: Preapproval testing experience at a single cancer centre

Esther Conde, Bárbara Angulo, Elisa Izquierdo, Luna Muñoz, Ana Suárez-Gauthier, Carlos Plaza, Nuria Dominguez, Maribel Torres, Luis Madrigal, Belén Rubio-Viqueira, Cristobal Belda-Iniesta, Manuel Hidalgo, Fernando López-Ríos

Research output: Contribution to journalArticle

Abstract

Aims: To study the ALK translocation in patients with advanced non-small-cell lung carcinomas (NSCLCs) seen at a European cancer centre, and its association with EGFR mutations, KRAS mutations and MET amplification. Methods and results: The study included samples from 86 patients diagnosed with advanced NSCLC. ALK fluorescence in-situ hybridization (FISH) was performed using the ALK break-apart probe set (Vysis). ALK FISH-positive cases were defined as those with more than 15% break-apart signals or isolated red signals in 50 cells. EGFR and KRAS mutations were determined by direct sequencing. All ALK-positive cases were analysed retrospectively for MET amplification using a FISH assay, and for ALK mutations by sequencing. We found nine (10.5%) ALK-positive cases, all in adenocarcinomas and the majority in female patients (88.9%). Signet ring cells were observed in four (44.4%) of the nine patients. None of the ALK translocated cases showed MET amplifications or EGFR, KRAS and ALK mutations. Conclusions: The prevalence of ALK translocation in an unselected population of European patients with advanced NSCLCs was 10%. This alteration was mutually exclusive with EGFR and KRAS mutations, as well as with MET amplification. If multiplexing is considered at the preanalytical phase, lung biopsy specimens are sufficient for performing several predictive assays.

Original languageEnglish (US)
Pages (from-to)609-616
Number of pages8
JournalHistopathology
Volume62
Issue number4
DOIs
StatePublished - Mar 2013
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Mutation
Fluorescence In Situ Hybridization
Neoplasms
Adenocarcinoma
Biopsy
Lung
Population

Keywords

  • ALK translocation
  • Lung cancer

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Conde, E., Angulo, B., Izquierdo, E., Muñoz, L., Suárez-Gauthier, A., Plaza, C., ... López-Ríos, F. (2013). The ALK translocation in advanced non-small-cell lung carcinomas: Preapproval testing experience at a single cancer centre. Histopathology, 62(4), 609-616. https://doi.org/10.1111/his.12037

The ALK translocation in advanced non-small-cell lung carcinomas : Preapproval testing experience at a single cancer centre. / Conde, Esther; Angulo, Bárbara; Izquierdo, Elisa; Muñoz, Luna; Suárez-Gauthier, Ana; Plaza, Carlos; Dominguez, Nuria; Torres, Maribel; Madrigal, Luis; Rubio-Viqueira, Belén; Belda-Iniesta, Cristobal; Hidalgo, Manuel; López-Ríos, Fernando.

In: Histopathology, Vol. 62, No. 4, 03.2013, p. 609-616.

Research output: Contribution to journalArticle

Conde, E, Angulo, B, Izquierdo, E, Muñoz, L, Suárez-Gauthier, A, Plaza, C, Dominguez, N, Torres, M, Madrigal, L, Rubio-Viqueira, B, Belda-Iniesta, C, Hidalgo, M & López-Ríos, F 2013, 'The ALK translocation in advanced non-small-cell lung carcinomas: Preapproval testing experience at a single cancer centre', Histopathology, vol. 62, no. 4, pp. 609-616. https://doi.org/10.1111/his.12037
Conde, Esther ; Angulo, Bárbara ; Izquierdo, Elisa ; Muñoz, Luna ; Suárez-Gauthier, Ana ; Plaza, Carlos ; Dominguez, Nuria ; Torres, Maribel ; Madrigal, Luis ; Rubio-Viqueira, Belén ; Belda-Iniesta, Cristobal ; Hidalgo, Manuel ; López-Ríos, Fernando. / The ALK translocation in advanced non-small-cell lung carcinomas : Preapproval testing experience at a single cancer centre. In: Histopathology. 2013 ; Vol. 62, No. 4. pp. 609-616.
@article{89810a42553842299a88a6ac2920a746,
title = "The ALK translocation in advanced non-small-cell lung carcinomas: Preapproval testing experience at a single cancer centre",
abstract = "Aims: To study the ALK translocation in patients with advanced non-small-cell lung carcinomas (NSCLCs) seen at a European cancer centre, and its association with EGFR mutations, KRAS mutations and MET amplification. Methods and results: The study included samples from 86 patients diagnosed with advanced NSCLC. ALK fluorescence in-situ hybridization (FISH) was performed using the ALK break-apart probe set (Vysis). ALK FISH-positive cases were defined as those with more than 15{\%} break-apart signals or isolated red signals in 50 cells. EGFR and KRAS mutations were determined by direct sequencing. All ALK-positive cases were analysed retrospectively for MET amplification using a FISH assay, and for ALK mutations by sequencing. We found nine (10.5{\%}) ALK-positive cases, all in adenocarcinomas and the majority in female patients (88.9{\%}). Signet ring cells were observed in four (44.4{\%}) of the nine patients. None of the ALK translocated cases showed MET amplifications or EGFR, KRAS and ALK mutations. Conclusions: The prevalence of ALK translocation in an unselected population of European patients with advanced NSCLCs was 10{\%}. This alteration was mutually exclusive with EGFR and KRAS mutations, as well as with MET amplification. If multiplexing is considered at the preanalytical phase, lung biopsy specimens are sufficient for performing several predictive assays.",
keywords = "ALK translocation, Lung cancer",
author = "Esther Conde and B{\'a}rbara Angulo and Elisa Izquierdo and Luna Mu{\~n}oz and Ana Su{\'a}rez-Gauthier and Carlos Plaza and Nuria Dominguez and Maribel Torres and Luis Madrigal and Bel{\'e}n Rubio-Viqueira and Cristobal Belda-Iniesta and Manuel Hidalgo and Fernando L{\'o}pez-R{\'i}os",
year = "2013",
month = "3",
doi = "10.1111/his.12037",
language = "English (US)",
volume = "62",
pages = "609--616",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The ALK translocation in advanced non-small-cell lung carcinomas

T2 - Preapproval testing experience at a single cancer centre

AU - Conde, Esther

AU - Angulo, Bárbara

AU - Izquierdo, Elisa

AU - Muñoz, Luna

AU - Suárez-Gauthier, Ana

AU - Plaza, Carlos

AU - Dominguez, Nuria

AU - Torres, Maribel

AU - Madrigal, Luis

AU - Rubio-Viqueira, Belén

AU - Belda-Iniesta, Cristobal

AU - Hidalgo, Manuel

AU - López-Ríos, Fernando

PY - 2013/3

Y1 - 2013/3

N2 - Aims: To study the ALK translocation in patients with advanced non-small-cell lung carcinomas (NSCLCs) seen at a European cancer centre, and its association with EGFR mutations, KRAS mutations and MET amplification. Methods and results: The study included samples from 86 patients diagnosed with advanced NSCLC. ALK fluorescence in-situ hybridization (FISH) was performed using the ALK break-apart probe set (Vysis). ALK FISH-positive cases were defined as those with more than 15% break-apart signals or isolated red signals in 50 cells. EGFR and KRAS mutations were determined by direct sequencing. All ALK-positive cases were analysed retrospectively for MET amplification using a FISH assay, and for ALK mutations by sequencing. We found nine (10.5%) ALK-positive cases, all in adenocarcinomas and the majority in female patients (88.9%). Signet ring cells were observed in four (44.4%) of the nine patients. None of the ALK translocated cases showed MET amplifications or EGFR, KRAS and ALK mutations. Conclusions: The prevalence of ALK translocation in an unselected population of European patients with advanced NSCLCs was 10%. This alteration was mutually exclusive with EGFR and KRAS mutations, as well as with MET amplification. If multiplexing is considered at the preanalytical phase, lung biopsy specimens are sufficient for performing several predictive assays.

AB - Aims: To study the ALK translocation in patients with advanced non-small-cell lung carcinomas (NSCLCs) seen at a European cancer centre, and its association with EGFR mutations, KRAS mutations and MET amplification. Methods and results: The study included samples from 86 patients diagnosed with advanced NSCLC. ALK fluorescence in-situ hybridization (FISH) was performed using the ALK break-apart probe set (Vysis). ALK FISH-positive cases were defined as those with more than 15% break-apart signals or isolated red signals in 50 cells. EGFR and KRAS mutations were determined by direct sequencing. All ALK-positive cases were analysed retrospectively for MET amplification using a FISH assay, and for ALK mutations by sequencing. We found nine (10.5%) ALK-positive cases, all in adenocarcinomas and the majority in female patients (88.9%). Signet ring cells were observed in four (44.4%) of the nine patients. None of the ALK translocated cases showed MET amplifications or EGFR, KRAS and ALK mutations. Conclusions: The prevalence of ALK translocation in an unselected population of European patients with advanced NSCLCs was 10%. This alteration was mutually exclusive with EGFR and KRAS mutations, as well as with MET amplification. If multiplexing is considered at the preanalytical phase, lung biopsy specimens are sufficient for performing several predictive assays.

KW - ALK translocation

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84874197111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874197111&partnerID=8YFLogxK

U2 - 10.1111/his.12037

DO - 10.1111/his.12037

M3 - Article

C2 - 23379755

AN - SCOPUS:84874197111

VL - 62

SP - 609

EP - 616

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 4

ER -